<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Spironolactone" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Spironolactone</book-part-id>
      <title-group>
        <title>Spironolactone</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>10</month>
          <year>2021</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Sotorasib" document-type="chapter">Sotorasib</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Spirulina" document-type="chapter">Spirulina</related-object>
    </book-part-meta>
    <body>
      <sec id="Spironolactone.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Spironolactone.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Spironolactone is an aldosterone receptor antagonist and potassium-sparing diuretic widely used in the therapy of edema, particularly in patients with cirrhosis in which hyperaldosteronism appears to play a major role. Spironolactone has been linked to rare cases of clinically apparent drug induced liver disease.</p>
        </sec>
        <sec id="Spironolactone.Background">
          <title>Background</title>
          <p>Spironolactone (spir on oh lak' tone) is a competitive inhibitor of the mineralocorticoid receptor in the late distal tubule and collecting duct of the kidneys, which causes a decrease in sodium reabsorption and potassium excretion in the distal tubule. As a result, spironolactone promotes a sodium diuresis, but maintains body potassium levels. Spironolactone is particularly helpful in edematous states caused or exacerbated by hyperaldosteronism, which is typical of the edema and ascites caused by cirrhosis. Because of its potassium-sparing actions, spironolactone is also used in combination with thiazide or loop diuretics in an attempt to prevent hypokalemia. Chronic low dose therapy with spironolactone has also been reported to improve survival in patients with heart failure after myocardial infarction. Spironolactone was approved for use in the United States in 1960 and continues to be widely used. Spironolactone is available in 25, 50, 75 and 100 mg tablets generically and under the brand name of Aldactone. Fixed combinations of spironolactone and hydrochlorothiazide are also available under the brand name Aldactizide. The typical dose of spironolactone is 25 mg one to three times daily initially, with modification of the dose based upon clinical efficacy and tolerance to maintenance doses of 75 to 450 mg daily. Spironolactone is usually well tolerated but can cause hyperkalemia and dehydration. In addition, spironolactone has antiandrogen-like effects and can have troublesome side effects of excess and abnormal hair growth and gynecomastia.</p>
        </sec>
        <sec id="Spironolactone.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Clinically apparent liver injury from spironolactone is rare and only a few instances have been reported as isolated case reports. The liver injury typically arises after 4 to 8 weeks of therapy and the pattern of serum enzyme elevations is usually hepatocellular or mixed. Immunoallergic features (rash, fever, eosinophilia) are rare as is autoantibody formation. Recovery has occurred within 1 to 3 months of stopping and all cases have been mild and self-limited in course (Case 1).</p>
          <p>Likelihood score: D (possible rare cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Spironolactone.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism of spironolactone hepatic injury is unknown, but is most likely due to a metabolic idiosyncrasy.</p>
        </sec>
        <sec id="Spironolactone.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>Reported cases of liver injury due to spironolactone have been mild with either no or minimal jaundice, and recovery within a few months of stopping the medication. Recurrence on rechallenge has been reported, but there is no information or cross reactivity to the hepatic injury with other diuretics. Because eplerenone has a similar chemical structure, it is likely to cause a similar hepatic injury.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="Diuretics" document-type="chapter">Diuretics</related-object>, Potassium-Sparing Diuretics</p>
          <p>Other Drugs in the Subclass: <related-object link-type="booklink" source-id="livertox" document-id="Amiloride" document-type="chapter">Amiloride</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Eplerenone" document-type="chapter">Eplerenone</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Triamterene" document-type="chapter">Triamterene</related-object></p>
        </sec>
      </sec>
      <sec id="Spironolactone.CASE_REPORT">
        <title>CASE REPORT</title>
        <sec id="Spironolactone.Case_1_Spironolactone_ind">
          <title>Case 1. Spironolactone induced liver injury.(<xref ref-type="bibr" rid="Spironolactone.REF.1">1</xref>)</title>
          <p>A 53 year old woman with primary hyperaldosteronism due to an adrenal adenoma was found to have serum enzyme elevations (ALT 430 U/L, AST 130 U/L, Alk P 225 U/L) without symptoms 1 month after starting spironolactone (100 mg three times daily). Spironolactone was stopped and serum enzymes fell into the normal range within the next two months. One year later, spironolactone was restarted (100 mg twice daily) and serum enzymes were again found to be abnormal one month later. She was not taking other medications and tests for hepatitis B and for autoantibodies were negative. There was no rash, fever or eosinophilia. A liver biopsy showed mild spotty hepatitis. Upon withdrawal of spironolactone, serum enzymes fell to normal within 6 weeks.</p>
          <sec id="Spironolactone.Key_Points">
            <title>Key Points</title>
            <table-wrap id="Spironolactone.Tc" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Spironolactone.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Spironolactone.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Spironolactone (100 mg 2-3 times daily)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Spironolactone.Tc_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Spironolactone.Tc_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Hepatocellular (R=6.7)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Spironolactone.Tc_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Spironolactone.Tc_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">Mild (enzyme elevations without symptoms or jaundice)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Spironolactone.Tc_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Spironolactone.Tc_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">4 weeks</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Spironolactone.Tc_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Spironolactone.Tc_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">6-8 weeks</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Spironolactone.Tc_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Spironolactone.Tc_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">None</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Spironolactone.Laboratory_Values">
            <title>Laboratory Values</title>
            <table-wrap id="Spironolactone.Td" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(U/L)</th>
                    <th id="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">GGT<break/>(U/L)</th>
                    <th id="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">15</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">80</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">10</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1 hd_h_Spironolactone.Td_1_1_1_2 hd_h_Spironolactone.Td_1_1_1_3 hd_h_Spironolactone.Td_1_1_1_4 hd_h_Spironolactone.Td_1_1_1_5 hd_h_Spironolactone.Td_1_1_1_6" colspan="6" valign="top" align="center" scope="col" rowspan="1">Spironolactone (100 mg three times daily) given for 1 month</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">4 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">430</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">185</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">90</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">6 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">255</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">225</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">140</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">8 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">70</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">150</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">80</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">12 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">8 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">35</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">105</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">20</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">24 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">20 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">30</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">90</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">1 year</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">1 year</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">25</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">85</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">20</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1 hd_h_Spironolactone.Td_1_1_1_2 hd_h_Spironolactone.Td_1_1_1_3 hd_h_Spironolactone.Td_1_1_1_4 hd_h_Spironolactone.Td_1_1_1_5 hd_h_Spironolactone.Td_1_1_1_6" colspan="6" valign="top" align="center" scope="col" rowspan="1">Spironolactone (100 mg two times daily) restarted for 1 month</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">4 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">140</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">145</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">45</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">6 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">125</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">10 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">6 weeks</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">20</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">80</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">30</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_1 hd_h_Spironolactone.Td_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
<bold>Normal Values</bold>
</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;40</bold>
</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;110</bold>
</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c; 40</bold>
</td>
                    <td headers="hd_h_Spironolactone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Spironolactone.Comment">
            <title>Comment</title>
            <p>This patient developed elevations in serum aminotransferases and alkaline phosphatase within a month of starting spironolactone. She was evidently asymptomatic and anicteric and the liver injury resolved rapidly upon withdrawal. The rare instances of hepatic injury reported with spironolactone use have been mild and self-limited. The recurrence of injury with the same latency and severity without immunoallergic features suggests metabolic idiosyncrasy as the cause of the hepatotoxicity.</p>
          </sec>
        </sec>
      </sec>
      <sec id="Spironolactone.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Spironolactone &#x02013; Generic, Aldactone&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Diuretics</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Spironolactone">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Spironolactone.CHEMICAL_FORMULA_AND_STRU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Spironolactone.Te" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Spironolactone.Te_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Spironolactone.Te_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Spironolactone.Te_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Spironolactone.Te_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Spironolactone.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Spironolactone</td>
                <td headers="hd_h_Spironolactone.Te_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134972759">52-01-7</ext-link>
</td>
                <td headers="hd_h_Spironolactone.Te_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C24-H32-O4-S</td>
                <td headers="hd_h_Spironolactone.Te_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134972759" document-id-type="sid" document-type="summary" object-id="134972759" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Spironolactone.CITED_REFERENCES">
        <title>CITED REFERENCES</title>
        <ref-list id="Spironolactone.CITED_REFERENCES.reflist0">
          <ref id="Spironolactone.REF.1">
            <label>1</label>
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Shuck</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Shan</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Owensky</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Leftik</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Cucinell</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Spironolactone hepatitis in primary hyperaldosteronism.</article-title>
              <source>Ann Intern Med</source>
              <year>1981</year>
              <volume>95</volume>
              <fpage>708</fpage>
              <lpage>10</lpage>
              <pub-id pub-id-type="pmid">7305153</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Spironolactone.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 13 October 2021</p>
        <ref-list id="Spironolactone.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Spironolactone.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Diuretic drugs. Drugs used in cardiovascular disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 662-4.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity of diuretics published in 1999 mentions that clinically apparent liver injury due to diuretics is rare; hepatocellular jaundice has been reported with triamterene; no mention of spironolactone).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Spironolactone.REF.de_marzio.2013">
            <mixed-citation publication-type="book">De Marzio DH, Navarro VJ. Hepatotoxicity of cardiovascular and antidiabetic drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 519-40.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of cardiovascular agents, mentions that thiazide diuretics can rarely cause cholestatic hepatitis; no mention of potassium sparing diuretics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Spironolactone.REF.jackson.2018">
            <mixed-citation publication-type="book">Jackson EK. Drugs affecting renal excretory function. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 445-70.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Spironolactone.REF.shuck.1981.708">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Shuck</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Shan</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Owensky</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Leftik</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Cucinell</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Spironolactone hepatitis in primary hyperaldosteronism.</article-title>
              <source>Ann Intern Med</source>
              <year>1981</year>
              <volume>95</volume>
              <fpage>708</fpage>
              <lpage>10</lpage>
              <annotation>
                <p>
<italic toggle="yes">(53 year old woman found to have elevations in ALT [430 U/L] and Alk P [225 U/L] 1 month after starting spironolactone, falling to normal in 2 months and rising again [ALT 140 U/L] within 2 months of rechallenge: Case 1, spironolactone).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">7305153</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.renkes.1995.376">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Renkes</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Gaucher</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Tr&#x000e9;chot</surname><given-names>P</given-names></name>
</person-group>
              <article-title>Spironolactone and hepatic toxicity.</article-title>
              <source>JAMA</source>
              <year>1995</year>
              <volume>273</volume>
              <fpage>376</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
<italic toggle="yes">(74 year old man developed jaundice 7 weeks after starting spironolactone, biopsy showing intrahepatic cholestasis, resolving within 3 months of stopping; no details given).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">7823379</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.thai.2001.180">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Thai</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>Sinclair</surname><given-names>RD</given-names></name>
</person-group>
              <article-title>Spironolactone-induced hepatitis.</article-title>
              <source>Australas J Dermatol</source>
              <year>2001</year>
              <volume>42</volume>
              <fpage>180</fpage>
              <lpage>2</lpage>
              <annotation>
                <p>
<italic toggle="yes">(50 year old woman developed fatigue and pruritus 6 weeks after starting spironolactone [bilirubin 2.3 mg/dL, ALT 997 U/L, Alk P 742 U/L], resolving within 3 months of stopping).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">11488711</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.russo.2004.1018">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Russo</surname><given-names>MW</given-names></name>
<name name-style="western"><surname>Galanko</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Shrestha</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Fried</surname><given-names>MW</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>P</given-names></name>
</person-group>
              <article-title>Liver transplantation for acute liver failure from drug-induced liver injury in the United States.</article-title>
              <source>Liver Transpl</source>
              <year>2004</year>
              <volume>10</volume>
              <fpage>1018</fpage>
              <lpage>23</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among ~50,000 liver transplants reported to UNOS between 1990 and 2002, 137 [0.5%] were done for idiosyncratic drug induced acute liver failure, none were attributed to a diuretic).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15390328</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.andrade.2005.512">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Andrade</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Lucena</surname><given-names>MI</given-names></name>
<name name-style="western"><surname>Fern&#x000e1;ndez</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Pelaez</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Pachkoria</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Garc&#x000ed;a-Ruiz</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Garc&#x000ed;a-Mu&#x000f1;oz</surname><given-names>B</given-names></name>
<etal/>
</person-group>
              <article-title>Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period.</article-title>
              <source>Gastroenterology</source>
              <year>2005</year>
              <volume>129</volume>
              <fpage>512</fpage>
              <lpage>21</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Reports of drug induced liver injury to a Spanish network found 570 cases; diuretics not mentioned as cause).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">16083708</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.bj_rnsson.2006.33">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bj&#x000f6;rnsson</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Olsson</surname><given-names>R</given-names></name>
</person-group>
              <article-title>Suspected drug-induced liver fatalities reported to the WHO database.</article-title>
              <source>Dig Liver Dis</source>
              <year>2006</year>
              <volume>38</volume>
              <fpage>33</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Survey of drug induced liver fatalities reported to WHO database between 1968-2003 revealed 4690 reports [89% from the US]; no diuretic found in the 20 most commonly implicated agents).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">16054882</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.sabat_.2007.1401">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Sabat&#x000e9;</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Ib&#x000e1;&#x000f1;ez</surname><given-names>L</given-names></name>
<name name-style="western"><surname>P&#x000e9;rez</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Vidal</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Buti</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Xiol</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Mas</surname><given-names>A</given-names></name>
<etal/>
</person-group>
              <article-title>Risk of acute liver injury associated with the use of drugs: a multicentre population survey.</article-title>
              <source>Aliment Pharmacol Ther</source>
              <year>2007</year>
              <volume>25</volume>
              <fpage>1401</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Population based survey of 126 cases of acute liver injury [24 with acute liver failure] due to drugs between 1993-1999 in Spain calculated relative risk of injury compared to the general population: hydrochlorothiazide was being taken by 7 and furosemide by 8 patients, but relative risk was not increased in comparison to a control group).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">17539979</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Bonkovsky</surname><given-names>HL</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>PB</given-names></name>
<name name-style="western"><surname>Davern</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Serrano</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Rochon</surname><given-names>J</given-names></name>
<collab>Drug Induced Liver Injury Network (DILIN)</collab>
</person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, no case was attributed to a diuretic).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF13">
            <element-citation publication-type="journal">
              <article-title>Drugs for hypertension.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2009</year>
              <volume>7</volume>
              <fpage>1</fpage>
              <lpage>10</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Brief overview of currently available drugs for hypertension with guidelines on their use and information on prices and toxicities: &#x0201c;thiazide diuretics are the first-line therapy for many patients with hypertension&#x0201d;).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">19107095</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.devarbhavi.2010.2396">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Devarbhavi</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Dierkhising</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Kremers</surname><given-names>WK</given-names></name>
<name name-style="western"><surname>Sandeep</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Karanth</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Adarsh</surname><given-names>CK</given-names></name>
</person-group>
              <article-title>Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality.</article-title>
              <source>Am J Gastroenterol</source>
              <year>2010</year>
              <volume>105</volume>
              <fpage>2396</fpage>
              <lpage>404</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 313 cases of drug induced liver injury seen over a 12 year period at a large hospital in Bangalore, India, none were attributed to a diuretic).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">20648003</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.ferrajolo.2010.721">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Ferrajolo</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Capuano</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Verhamme</surname><given-names>KM</given-names></name>
<name name-style="western"><surname>Schuemie</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Rossi</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Stricker</surname><given-names>BH</given-names></name>
<name name-style="western"><surname>Sturkenboom</surname><given-names>MC</given-names></name>
</person-group>
              <article-title>Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.</article-title>
              <source>Br J Clin Pharmacol</source>
              <year>2010</year>
              <volume>70</volume>
              <fpage>721</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 624,673 adverse event reports in children between 2000 and 2006 in the WHO VigiBase, no diuretic was mentioned among the 30 most common causes of liver injury).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">21039766</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.reuben.2010.2065">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Reuben</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Koch</surname><given-names>DG</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>WM</given-names></name>
<collab>Acute Liver Failure Study Group</collab>
</person-group>
              <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
              <source>Hepatology</source>
              <year>2010</year>
              <volume>52</volume>
              <fpage>2065</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, of which none were attributed to a diuretic).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">20949552</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.bj_rnsson.2013.1419">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bj&#x000f6;rnsson</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Bergmann</surname><given-names>OM</given-names></name>
<name name-style="western"><surname>Bj&#x000f6;rnsson</surname><given-names>HK</given-names></name>
<name name-style="western"><surname>Kvaran</surname><given-names>RB</given-names></name>
<name name-style="western"><surname>Olafsson</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
              <source>Gastroenterology</source>
              <year>2013</year>
              <volume>144</volume>
              <fpage>1419</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
<italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, none of which were attributed to a diuretic).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">23419359</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Hern&#x000e1;ndez</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Bessone</surname><given-names>F</given-names></name>
<name name-style="western"><surname>S&#x000e1;nchez</surname><given-names>A</given-names></name>
<name name-style="western"><surname>di Pace</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Brahm</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Zapata</surname><given-names>R, A</given-names></name>
<name name-style="western"><surname>Chirino</surname><given-names>R</given-names></name>
<etal/>
</person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to a diuretic).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Bonkovsky</surname><given-names>HL</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Stolz</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Talwalkar</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Reddy</surname><given-names>KR</given-names></name>
<etal/>
<collab>United States Drug Induced Liver Injury Network</collab>
</person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to a diuretic).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Spironolactone.REF20">
            <element-citation publication-type="journal">
              <article-title>Drugs for hypertension.</article-title>
              <source>Med Lett Drugs Ther.</source>
              <year>2020</year>
              <volume>62</volume>
              <issue>1598</issue>
              <fpage>73</fpage>
              <lpage>80</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Concise summary of efficacy, safety and costs of drug therapy of hypertension including the diuretics, focusing upon relative usefulness; no mention of hepatic adverse events).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">32555118</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Spironolactone.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Spironolactone/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Spironolactone: from PubMed.gov</ext-link>
</p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Spironolactone">Trials on Spironolactone: from ClinicalTrials.gov</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
